GlassScriptPhysician profile
Daniel J Robinson
NPI 1457355307
$1,737.59
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $242 · 2020: $132 · 2021: $435 · 2022: $375 · 2023: $243 · 2024: $310.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $553.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $553.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $969.33 | 2019-2024 | Clareon, Argos, Rocklatan |
| Sun Pharmaceutical Industries INC. | $152.36 | 2019-2024 | |
| Allergan, INC. | $131.90 | 2019-2021 | |
| Abbvie INC. | $71.35 | 2023-2024 | Lumigan, Alphagan P |
| Aerie Pharmaceuticals, INC. | $63.46 | 2021 | |
| Ocular Therapeutix, INC. | $55.73 | 2023 | Dextenza |
| Kala Pharmaceuticals, INC. | $42.48 | 2019-2021 | |
| Thea Pharma INC. | $39.53 | 2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $36.88 | 2019-2020 | |
| Biotissue Holdings INC. | $35.86 | 2020-2022 | |
| Oyster Point Pharma, INC. | $24.79 | 2024 | Ryzumvi, Tyrvaya |
| Carl Zeiss Meditec USA, INC. | $23.07 | 2023 | Callisto Eye |
| Rxsight INC | $19.78 | 2022 | |
| Eyepoint US, INC. | $19.68 | 2021 | |
| Horizon Therapeutics Plc | $16.06 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $13.30 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $12.08 | 2020 | |
| Quidel Corporation | $9.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Robinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.